share_log

B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $15

Benzinga ·  Oct 18 00:59  · Ratings

B of A Securities analyst Tazeen Ahmad maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $13 to $15.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment